Czech National Bank Raises Position in Hologic, Inc. $HOLX

Czech National Bank increased its position in Hologic, Inc. (NASDAQ:HOLX) by 5.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,471 shares of the medical equipment provider’s stock after acquiring an additional 2,933 shares during the period. Czech National Bank’s holdings in Hologic were worth $3,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Invesco Ltd. raised its stake in Hologic by 18.8% in the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Hologic by 1.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after acquiring an additional 69,878 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Hologic by 0.8% in the 1st quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock worth $216,973,000 after acquiring an additional 29,133 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Hologic by 8.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock worth $175,331,000 after acquiring an additional 213,366 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $66.33 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The business’s 50-day moving average price is $66.47 and its 200 day moving average price is $62.75. The firm has a market cap of $14.75 billion, a P/E ratio of 27.52, a P/E/G ratio of 2.47 and a beta of 0.57.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HOLX. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 8th. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, September 15th. Argus lifted their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $79.38.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.